raw data set, bounds estimations for change in waist circumference revealed tighter ranges in men than women. Conclusion: Future studies may be able to take advantage of multiple approaches, including the method we describe, to identify and quantify the presence of TRH in studies of WL or related outcomes.
Introduction
Examinations in the scientific literature have evaluated genetic associations between specific genes, loci and single nucleotide polymorphisms and human and/or animal obesity. The heritability estimate of the human body mass index (BMI) is approximately 0.65 [1, 2] . Additionally, some genetic associations have been examined pertaining to human and animal thinness [3] . More recently, studies have been performed to evaluate the genetic influence on the weight loss (WL) process, seeking to understand if the use of genetic information about a WL patient can determine a more personalized treatment plan or predict the amount of weight that can be lost [4, 5] . Yet to date, genetic associations that disappointingly explain only a small amount (<7%) of the variance in BMI [6] within populations and similarly small magnitudes of WL being explained by genotypes are reported in WL studies [5] . Our focus here is on variability in treatment response across individuals, such as the effect of an intervention on BMI loss versus a control intervention. This is what is referred to herein as WL treatment response variability or heterogeneity.
Of the current methods for attempting WL, bariatric surgery has the largest average effect (loss from baseline weight ranging from 15 to 30% within the first year after the surgery) [7] . Yet there is significant weight regain within 5 years after the surgery, although some patients maintain WL for up to 10 years [8] . Outcomes (i.e. gains or losses that are observed over time) are highly variable, depending upon other aspects of postsurgical care [9] . With the more common WL methods using dietary and physical activity interventions, outcomes average between 2 and 5 kg with diet alone and between about 0 and 2 kg with exercise alone [10] . These effects often plateau within about 6 months with some regain typically seen by 12 months [10] . Observed WL effects often exhibit nonnormal distributions with large variances [4] . Thus far, sufficient predictive models using genetic information are not available to reliably predict if an individual will respond to a given WL intervention and to what degree [4] . It is often poorly understood how much treatment response heterogeneity might be present in the first place and whether a search for such gene-treatment interactions that explain this heterogeneity will be fruitful [11] . However, much data exist to estimate the range of likely responses to present-day treatments. Such analytic approaches can inform future investigations of the potential genetic contribution of variability in WL treatment response in humans.
Present Aim
We aimed to quantify the upper and lower bounds of WL treatment response heterogeneity using summary statistics from published randomized controlled trials and a raw data set. First, we discuss the statistical considerations for such approaches, followed by 2 example illustrations using summary statistics from 66 published trials and raw data from a single, large trial.
Variability in Treatment Response
Variability in treatment response refers to the idea that the true effect of a treatment for one individual will be different from that of another. Some have called this 'individual treatment heterogeneity' [12] or 'subject-treatment interaction' [13] . (Of note, throughout this paper, we refer only to statistical interactions and do not attempt to quantify specific gene interactions -see Wang et al. [14] for a more thorough explanation of types of interactions within the genetic framework.) To formally define this idea, suppose an outcome of interest (e.g., change from baseline in weight or BMI) after exposure to a treatment, noted as b , is given by Y b , and that the outcome after exposure to a different treatment, noted as a (perhaps a control treatment), is given by Y a . The bivariate pair of outcomes ( Y a , Y b ) is called potential outcomes [15] and the potential outcomes' framework has become widely used in statistics for studying causal effects in randomized and nonrandomized settings.
A true, singular, causal effect of treatment b with respect to treatment a , at a particular point in time, is given by D = Y b -Y a , which represents an individual WL of a subject when on treatment b versus when on treatment a (control). D cannot be observed for an individual since an individual is either assigned to the treatment or the control group at a given time. This has been referred to as the fundamental problem of causal inference [16] . It is worth noting that a change in a particular subject's weight over a given time period may be due to the effect of treatment or other factors (observed or unobserved) that were at play during the time period. The true effect of the treatment for an individual cannot be separated from these other factors.
Often, E ( D ) = μ D (mean treatment effect) is of greatest interest. Here, we consider a measure of individual treatment heterogeneity given by the standard deviation
This standard deviation cannot be estimated from observable data because there is no information on the correlation between Y b and Y a . Yet, estimable bounds exist that are defined by setting this nonestimable correlation equal to 1 and -1. We denote these bounds as σ D min , σ D max , where
and where σ b and σ a are the standard deviations of outcomes on treatments b and a , respectively. Evidence of heteroscedasticity across the 2 treatment groups is an indication that treatment heterogeneity is present in the population from which samples were obtained. be conducted based on summary statistics from a study or several studies, again assuming that outcomes are at least approximately normally distributed. We illustrate this in the next section. When treatment heterogeneity is likely to be present in the population from which samples were obtained, a secondary question is whether this possible heterogeneity has important consequences that should be investigated. One consequence of this heterogeneity is that the effect of treatment b with respect to treatment a may be in opposite directions across different individuals or subsets of individuals, with one treatment appearing to have higher efficacy for some and the other appearing to have higher efficacy for others. The term qualitative interaction has been used to describe this situation at the subset level [17, 18] . A 'quantitative' interaction [18] exists when the magnitudes of the effect of treatment b versus that of treatment a differ across subsets, but are in the same direction. Transformations are sometimes used to remove interactions so that, on the transformed scale, more comprehensive statements about treatment effects can be made. If measurements are obtained on a clinically meaningful scale and subjecttreatment interaction is present in the population on that scale, transforming the data with monotonic but nonlinear transformations may eliminate such interactions. Doing so is not inherently correct or incorrect but, with clinically meaningful scales, one might argue that any assessment of subject-treatment interaction should be done on the original scale of measurement. However, if there are no qualitative interactions present in the population when using a clinical meaningful scale of measurement, then for some applications the question of variability is of lesser consequence because one treatment appears to be superior to another across all subjects. In such a case, a transformation may restore homoscedasticity and facilitate the analysis. In studies that exhibit evidence of a positive mean treatment effect, μ D > 0, treatment heterogeneity could result in a proportion of individuals that have an effect in the opposite direction from the mean, i.e. a value of D < 0. If an outcome such as WL is assumed to be a variable that is normally distributed, then this proportion is quantified by
where Φ denotes the cumulative distribution function of a standard normal distribution. P -D cannot be estimated for the same reason that σ D cannot be estimated. However, estimable bounds can be given by
The Role of a Covariate The above discussion does not consider the use of information on other variables that is available in most human WL studies. Here we consider the role of commonly used covariates -those variables not affected by treatment, such as age, gender, race, and other demographics. We also examine effects of treatment using baseline body composition in the model. These variables play 2 roles: (1) they may provide further evidence that treatment heterogeneity is present, and (2) they allow us to refine or tighten estimable bounds for treatment heterogeneity.
Consider, as in Gadbury et al. [19] , a continuous covariate Z with a mean μ Z and variance σ Z 
as has been shown by Gadbury et al. [19] . Several observations can be made regarding this expression. First, all parameters in it can be estimated using observed data except the partial correlation. 
, and the last equality cannot be tested using observed data. Thus, either the presence of heteroscedasticity of residual variances across the 2 treatment groups or a covariate-treatment interaction (or both) provides evidence that treatment heterogeneity is present. A similar result holds for a categorical covariate and has been shown in Poulson et al. [12] . With a continuous covariate, tightened bounds for σ D become 130 ment heterogeneity has estimable bounds resembling those given in eq. 1 but using conditional standard deviations conditioned on Z . These bounds can be interpreted as bounds for treatment heterogeneity of subpopulations defined by values of Z , i.e. bounds for σ D | Z . If the mean treatment effect is positive for a given subpopulation, then the proportion of the subpopulation having a negative effect are bounded by quantities like those in eq. 2 but instead using the conditional mean and standard deviations of subpopulations given a value of Z . An example of this is given in Poulson et al. [12] .
The results shown above for the use of one covariate generalize to the use of multiple covariates and the tightness of the bounds depend on the predictive capability of the set of covariates, i.e. their ability to reduce the conditional standard deviations σ Y b | Z and σ Y a | Z . The derivation of the technique for using multiple covariates is given in the Appendix.
Results

Evaluating Treatment Heterogeneity in Summary Statistics from Multiple Studies
In a literature search on adult obesity randomized controlled trials published between January 2007 and July 2009, 166 studies were identified that reported measurements of weight change, BMI change, or both. Of these, 66 studies were identified that reported mean and standard deviations for WL as well as mean and standard deviations for baseline weight (for the bibliography of the included studies, see online suppl. material at www. karger.com/doi/10.1159/000351738). All studies were evaluated according to the following inclusion criteria: (1) the data were from human studies; (2) the study was a randomized controlled trial; (3) the study had a total sample size of at least 30 participants at enrollment; (4) the study protocol included an intervention period of at least 8 weeks; (5) WL and/or weight gain prevention was a primary or secondary outcome variable, and (6) the publication was available in the English language. Some of these studies had multiple treatment arms, but the present focus is only the primary intervention arm and the control arm. Of the 66 studies initially analyzed, intervention types were: behavioral/lifestyle/educational in 25.8%, diet only in 36.4%, exercise only in 4.5%, mixed (more than one of any type) in 21.2%, and pharmaceutical in 12.1%. For these 66 studies, single-or double-blind designs were reported in 51.5% overall, and 17.6% of the behavioral/lifestyle/educational, 70.8% of the diet, 33.3% of the exercise, 35.7% of the mixed, and 100% of the pharmaceutical studies reporting single-or double-blind designs. The intervention periods ranged from 8 weeks to 3 years, with a mean of 29 weeks and a mode of 12 weeks.
To assess what proportion of studies exhibit evidence of treatment heterogeneity, a hypothesis test of the form 2 are the population variances of WL in the control and treatment groups, respectively. This was used as a test for evaluating whether there was evidence that σ D min > 0. Of the 66 studies, 17 (26%) showed evidence that treatment heterogeneity was present, as compared to 3 (5%) that would have been expected by random chance. Thus, one could surmise that an estimated proportion of 0.26 studies [with a standard error (SE) of 0.05] exhibit evidence of treatment heterogeneity, solely on the basis of summary measures that were available on the studies considered here. There is no clear evidence of association between those studies that showed evidence of treatment heterogeneity and the primary intervention type, the duration of the intervention, or the baseline mean weight/BMI.
We now illustrate the use of estimated values of P -
and Pmax D given in eq. 2. Of the 66 studies, 32 indicated a positive mean treatment effect that was at least marginally significant (a standardized mean difference >2). Of these 32, 12 exhibited evidence that treatment heterogeneity was present, i.e. σ D min > 0. However, only 3 studies had a point estimate of Pmin D that exceeded 0.05 (i.e. an estimated minimum percentage of the population having a negative treatment effect >5%). This suggests that a proportion of 0.094 of the sampled studies (i.e. 3 out of 32) indicate treatment heterogeneity, where more than 5% of a population have a treatment effect in the opposite direction from the mean effect. An effective method to estimate SEs for estimated Pmin D is the use of bootstrap techniques as was done in Gadbury et al. [19] . However, this requires raw data that were not available for all of these studies.
Of the 32 studies with evidence of a positive mean treatment effect, 4 had an estimated Pmax D that was <0.09 (the estimated Pmin D was close to zero for these 4 studies). These studies had a relatively large estimated mean effect and a small estimate for σ D max . When the estimated Pmax D is small, it suggests that most of the individuals should have an effect of treatment in agreement with the mean effect. For 3 of these 4 studies, diet was the primary intervention. All bounds were estimated using only informa- 
Illustration with a Raw Data Set and Covariates
The PREMIER weight loss trial [20] was a randomized trial to investigate the effects of 2 multicomponent lifestyle interventions on blood pressure in a large sample of 761 adults (61.9% female, 34% African American) who were assigned to either (1) a behavioral lifestyle intervention that implemented established recommendations, (2) a behavioral lifestyle intervention of established recommendations plus the DASH (dietary approaches to stop hypertension) diet, or (3) an advice-only standard of care group for a period of 18 months. Participants had a mean age ± SD of 49.3 ± 8.8 years and a BMI of 33.0 ± 5.7 at study entry [4, 21] .
Here we illustrate treatment heterogeneity using waist circumference (WC) loss as a primary outcome (positive numbers were a loss in WC during the trial). We selected this outcome variable as it has predictive utility in health outcomes and is linked to genetic influences [4, 21] . The treatment group considered is a 'comprehensive plus DASH lifestyle intervention', in which participants receive a behavioral intervention program designed to promote the DASH dietary pattern (increased intake of fruits, vegetables, and low-fat dairy products, and reduced intake of saturated fat and total fat) in addition to the longstanding recommendations for blood pressure control (reduced salt intake, increased physical activity, reduced alcohol intake, and WL, if overweight). The control group is an 'advice-only' control arm, in which participants receive information on how to reduce salt intake, increase physical activity, reduce alcohol intake, and lose weight if overweight. The information provided to participants is similar to that in the information-oriented programs that are sometimes provided as part of routine medical care.
The 253 individuals in the control arm lost on average 1.17 cm in WC with a standard deviation of 7.24 cm. The 254 subjects in the treatment arm lost on average 3.64 cm in WC with a standard deviation of 6.89 cm. The standardized mean difference is 3.93, and a two-tailed t test indicates that the treatment arm lost significantly more WC than the control arm (p = 0.0001).
Since the raw data are available, bootstrap [22] can be used to estimate SEs for estimated bounds for treatment heterogeneity. Lower and upper bounds for σ D given in eq. 1 are estimated to be 0.36 (SE = 0.44) and 14.13 (SE = 0.63), respectively. From the SEs, one can see that the lower bound is not significantly different from zero. An F-test for evaluating whether σ D min > 0 gives also no significant results (F = 1.11. p = 0.41, two-tailed). However, only using the primary outcome data, σ D is estimated to be as high as 14.13. The proportion of the population that could have lost more WC in the control arm versus the treatment arm is given by the bounds in eq. 2. The estimated lower bound is very near zero, but the estimated upper bound is 0.43 with a bootstrap SE of 0.018. Without more information, one cannot tell whether it is more likely that all subjects would lose more WC in the treatment relative to the control arm or whether up to 43% would have lost more WC by being assigned to the control condition instead.
We illustrate the use of baseline WC in explaining part of treatment heterogeneity when interactions may be present. This variable was chosen as the variable Z in the discussion above to illustrate the interaction effect shown in eq. 3 for treatment heterogeneity. A model fitting WC loss against treatment and baseline WC shows a significant treatment-baseline interaction (p = 0.01). The estimated value of (
is 2.45, which is the estimated amount of the variance of individual treatment effects, σ D
2
, that is explained by the interaction. Refined bounds for σ D are then estimated to be 1.56 (SE = 0.57) and 13.56 (SE = 0.59). The lower bound is now significantly different from zero, but the treatment heterogeneity is explained by an interaction between treatment and baseline WC. Further examination of the interaction reveals that the treatment has a significant effect on reducing WC relative to control for those individuals with a baseline WC below the third quartile. As baseline WC becomes larger, the treatment does not appear to have an effect that is different from the control condition. There is no evidence that the treatment is more effective than the control condition in reducing WC for individuals above the third quartile at baseline.
Using several covariates, e.g., baseline values for weight, BMI, and WC as well as age, height, race, and sex, and using the derivation shown in the Appendix, the estimated lower and upper bounds for σ D are further tightened to be 3.03 and 12.92, respectively. Fitting a linear model with these covariates and all treatment covariate interactions, and then reducing it using backward stepwise selection using the AIC statistic as a criterion leads to a model with an R 2 value of 0.22. Thus, only 22% of the variability in WC loss is explained by the use of several covariates, indicating that much of the variability in WC change remains unexplained. Thus, unexplainable individual treatment heterogeneity remains. Tightening bounds further requires the identification of variables that are predictive of success to one particular treatment versus another.
It may be of interest to evaluate whether one subset of a population exhibits more heterogeneity in treatment response than another. Subsets may be delineated by race, age categories, gender, etc. Here we illustrate such an evaluation using gender. Using no covariates, table 1 shows the results for a mean treatment effect and estimated σ D min , σ D max , Pmin D and Pmax D for each gender separately. SEs were estimated using the nonparametric bootstrap [22] with 2,000 samples within the treatment groups. The results show that female subjects in the treatment group lost on average 1.43 cm more in WC than those in the control group. This difference was not statistically significant (p = 0.107). Male subjects in the treatment group lost 4.07 cm more than those in the control group, with a p value rounded to zero out to 4 decimal places. The bounds for treatment heterogeneity are tighter for male subjects than females. There is an estimated minimum proportion of 0.065 of the male subjects who would have a larger loss in WC on the control treatment, but the SE shows this proportion to not be statistically different from zero. However, with no additional information, this proportion could be as large as 0.35. The estimated minimum proportion of female subjects who would lose more WC under the control condition is 0.19. The large SE for this proportion is due to the mean effect not being statistically significant, and the estimated minimum proportion can vary widely in such cases. Table 2 shows the bounds for treatment heterogeneity using baseline WC as a covariate. One can see that the estimated bounds for both genders are tightened but more so for females. This is because the baseline WC and treatment-baseline interaction were highly significant for females (p = 0.001) but not for males (p = 0.787; fig. 1 a  and b, respectively) . Thus, the baseline covariate did not explain any treatment heterogeneity for male subjects, nor did it tighten the estimated bounds. SEs suggest that the estimated minimum bounds for both genders are greater than zero. SEs were estimated using 2,000 bootstrap samples. Data source: raw data obtained from Svetkey et al. [20] . Table 3 shows the tightened bounds using baseline weight, baseline WC, baseline BMI, age, and race as covariates. Using the formula in the Appendix, one can see a further tightening of the bounds (particularly in males) as these additional covariates are added. Unlike baseline WC, the added variables are significant in explaining variability in WC change due to treatment, thereby tightening estimated bounds for treatment heterogeneity. However, the estimated minimum and maximum bounds remain wide in this model. Performing some variable selection in a linear model that includes interactions as covariates to select a 'best' model for each gender, the resulting R 2 value is only 0.22 for females and 0.21 for males, indicating that these variables only account for a relatively small proportion of the variability in WC change observed during the various interventions studied.
Discussion and Summary
Our method and examples illustrate the application of determining bounds of treatment variability in human WL studies using existing data. Our estimates of upper bounds in the examples given show that as many as 30-40% of a sampled population could have had an effect of treatment in the opposite direction from the mean treatment effect. However, minimum bounds did not indicate that such a positive proportion must be present. Estimated bounds tended to be wide when only primary outcome variables were available. It is interesting to note that the F-test that is sometimes used for equality of variance in 2 sample studies also served to evaluate whether there is evidence of treatment heterogeneity in the population, i.e. σ D min > 0. In the example of the raw data set, we illustrate a gender-treatment interaction. This type of interaction may be frequently overlooked in studies that do not analyze outcome data separately by gender for mixed samples. In turn, this could result in a reduced overall effect due to the choice of analysis and not the type of intervention. Future studies of genetic relationships to WL outcomes should examine gender data separately. The strengths of these analyses are in the rich data sets used for illustrating the methods described.
We must acknowledge the limitations of the conclusions drawn. First, replication with other data sets is advised as our selections were not comprehensive or systematic. The 66 studies used had a short date range (January 2007 to July 2009), but they were part of a systematic re- view project [23] . Second, the analysis and examples we discussed are unable to directly address quantification or specific interactions with potential genetic or epigenetic influences on WL treatment response. Additionally, an assumption of normal distributions of WL outcomes may not be supported in all studies. Further, we cannot quantitatively assess influence of bias due to nonblinded study designs on the heterogeneity of treatment response observed. Of the 66 studies initially examined, 51.5% had designs of either single or double blinding. Of the 32 assessed that demonstrated a positive mean treatment effect that was at least marginally significant, 48.4% had designs of either single or double blinding. The relative proportions of studies that have some type of blinding among the intervention types were also roughly equivalent in the 66 initial studies examined as compared to the 32 analyzed.
For the pharmaceutical studies analyzed, we cannot separate the heterogeneity of response observed to any standard of care component in addition to the response to drug effects. Since these represented approximately 16% of all studies analyzed, we estimate the influence of this type of potentially 'additive' heterogeneity to be relatively small, but this is not estimated in the present analysis. We provide a framework for future studies in which to add genetic or gene regulation data, allowing for quantification of the range of responses to WL interventions when individual risk genes (and/or gene regulation mechanisms) are more clearly identified as they pertain to the degree and variation of treatment response. Estimated minimum and maximum bounds for treatment heterogeneity were computed by setting a nonestimable correlation (or partial correlation when covariates were used) equal to 1 and -1. In the case of no covariates, one might assume that the correlation between potential outcomes Y a and Y b is more likely to be positive than negative because the 2 outcomes are defined to be potentially measurable on the same subject. Thus, bounds could be subjectively tightened by restricting the range of the nonestimable correlation to positive values. With covariates, one may assume that the 2 potential outcomes, given the covariates, may be in a restricted range (perhaps a range around zero) and, thus, facilitate tightening bounds on treatment heterogeneity. While these assumptions may certainly be plausible for certain applications, they are still unable to be verified with the observed data.
Other studies are necessary to further refine bounds for the variance unaccounted for, likely due to nongenetic or epigenetic components such as life-course factors (e.g., developmental factors, lifestyle habits, and physiological adaptations to environments), unknown medical conditions, effects from receiving other WL treatments, and levels of compliance with treatments. To reduce these sources of variance, large and highly controlled studies (e.g., in metabolic units rather than in free-living samples) are needed. In the meantime, meta-analytic approaches can be applied to these areas where such existing data have been quantified to begin to refine estimates of the interindividual variability of these components on WL outcomes.
and these tightened bounds lead to tighter bounds for σ D .
